Harris Williams & Co. Advises Caprion in its Sale to CGP
News Jul 31, 2012
Harris Williams & Co. has announced the sale of Caprion Proteomics, Inc. (Caprion), the leading provider of integrated proteomic biomarker and target identification solutions and immune monitoring services, to Chicago Growth Partners (CGP).
Caprion was a portfolio company of Great Point Partners (GPP). Harris Williams & Co. acted as an advisor to Caprion.
The transaction closed on July 19, 2012 and was led by James Clark, Turner Bredrup, Geoff Smith, Whit Knier and Paul Hepper from the firm's Healthcare & Life Sciences (HCLS) Group.
"Caprion has established itself as the market leader in providing outsourced proteomic biomarker discovery and immune monitoring services for its growing list of blue-chip pharmaceutical and biotechnology clients. Caprion is well positioned as the pharmaceutical industry continues to outsource critical elements of the drug development process to maximize returns on its research and development spend," said James Clark, a managing director in Harris Williams & Co.'s HCLS Group.
Caprion is the leading provider of proteomics services to many of the largest and most successful pharmaceutical and biotechnology companies, as well as several government research institutions.
Caprion's key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development.
The company's proprietary CellCarta technology is the leading biomarker discovery and validation platform in the growing field of proteomics, and has overcome technical limitations of earlier proteomics technologies by developing and effectively putting into industrial practice a powerful proteomics engine for highly multiplexed, unbiased measurement of protein abundance differences across large sample sets.
GPP, based in Greenwich, CT, is a leading healthcare investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds.
GPP has provided growth equity, growth recapitalization and management buyout financing to more than 100 healthcare companies.
The private equity fund invests in profitable companies across all sectors of the healthcare industry including behavioral health, biologics manufacturing, healthcare services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals and workers' compensation.
For over 25 years and across more than 100 growth companies, the principals of CGP have partnered with quality management teams to help facilitate their growth objectives.
CGP executes its growth-focused investment strategy across four industries: education, tech-enabled services, healthcare and industrial growth. CGP currently manages $1.2 billion of committed capital and has offices in Chicago and La Jolla.
Bioinformatics to Help Understand Intrinsically Disordered ProteinsNews
Over the last several decades, scientists have sequenced 85 million unique proteins, structured and unstructured alike, but still don’t know what the vast majority of these proteins do.READ MORE
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Protein Discovery Could Lead to Better Diagnosis of StressNews
Researchers have found a protein that is present in people while they are in stressful situations. The discovery could lead to identifying new ways to predict, diagnose and treat stress.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
11th Edition of International Conference on Proteomics 2018
Mar 22 - Mar 23, 2018